确定COVID-19相关心力衰竭中的潜在生物过程和关键目标
Jia Li1, Zhifu Guo1, Xiaowei Song1
1Department of Cardiology, Changhai Hospital, Naval Medical University, Shanghai, China.
Heliyon
|August 9, 2023
概括
这项研究确定PYGM和BLM是参与COVID-19相关心力衰竭的关键基因,建议它们是潜在的治疗标. 生物信息学分析揭示了共享的生物学途径,为疾病机制提供了洞察力.
科学领域:
- 心血管生物学 心血管生物学
- 传染性疾病 传染性疾病
- 生物信息学是一种生物信息学.
背景情况:
- 由SARS-CoV-2引起的新型冠状病毒肺炎 (COVID-19) 是一个全球性流行病.
- 心力衰竭 (HF) 是心血管疾病的关键阶段.
- 新出现的证据将SARS-CoV-2感染与心脏并发症联系起来,包括心力衰竭.
研究的目的:
- 使用生物信息学识别COVID-19相关心力衰竭的关键生物过程和治疗点.
- 分析COVID-19和心力衰竭之间的共同遗传因素.
主要方法:
- 从GEO数据库获取COVID-19和心力衰竭基因表达数据集.
- 应用权重基因共同表达网络分析 (WGCNA) 来识别关键模块和枢纽基因.
- 基因组的交集以找到共享的基因并执行基因本体学 (GO) 和KEGG通路丰富分析.
主要成果:
- 在COVID-19和心力衰竭数据集之间识别了11个共享基因.
- 选PYGM和BLM作为潜在参与COVID-19相关心力衰竭的关键基因.
- 丰富分析突出了诸如粉和糖代谢,同源重组,Fanconi贫血和胰岛素抵抗等途径.
结论:
- PYGM和BLM代表了COVID-19相关心力衰竭的潜在干预目标.
- 鉴定的生物过程为了解COVID-19相关心力衰竭背后的机制提供了洞察力.
- 这项研究为开发这种疾病的新型治疗策略提供了基础.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:29Pathophysiology of Cardiac Performance
703
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
703
01:27Heart Failure I: Introduction
16
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
16